Table 1

Baseline characteristics

Ciclesonide (n=15)Placebo (n=15)
Age (years)*48.5 (11.6)53.3 (13.3)
Female (%)7 (47%)7 (47%)
BMI*29.9 (4.6)27.3 (4.6)
ICS dose (µg BDP)†1600 (1200–2000)1600 (1000–2000)
Regular prednisolone (%)6 (40%)4 (27%)
Prednisolone dose (mg)†5 (5–10)5 (5–10)
FEV1 (L)*2.0 (0.6)1.8 (0.6)
FEV1 (% predicted)*61.8 (14.9)60.1 (9.4)
ACQ score*3.2 (1.0)2.8 (0.8)
AQLQ score*4.0 (1.1)4.3 (1.1)
FeNO (ppb)‡58.9 (0.3)43.7 (0.3)
Corrected alveolar NO (ppb)†3.3 (0.6–6.4)2.6 (1.4–4.5)
Sputum eosinophils (%)†23 (7.5–51.1)9.6 (6.8–31.5)
Sputum neutrophils (%)†43.5 (27.5–73.0)50.5 (31.8–70.5)
Blood eosinophils (×109/L)†0.5 (0.5–0.9)0.4 (0.2–0.7)
Blood neutrophils (×109/L)†4.5 (3.6–6.3)5.0 (3.7–6.6)
Serum cortisol (nmol/L)†266 (217–414)254 (191–294)
  • *Mean (SD).

  • †Median (IQR).

  • ‡Geometric mean (log SD).

  • ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BDP, beclometasone dipropionate; BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; NO, nitric oxide.